Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 AlteredExpression disease BEFREE Silibinin inhibits endometrial carcinoma via blocking pathways of STAT3 activation and SREBP1-mediated lipid accumulation. 30452972 2019
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 Biomarker disease BEFREE It was demonstrated that Sirtuin 1 (SIRT1), forkhead transcription factor 1 (FoxO1) and sterol regulatory element binding protein-1 (SREBP-1) may act as a pathway and play crucial roles in the development of EC in our previous studies. 30206735 2018
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 Biomarker disease BEFREE However, the association between FOXO1 and SREBP1 in EC is not clear. 28356952 2017
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 AlteredExpression disease BEFREE The aim of this study was to investigate endometrial sterol regulatory element binding protein-1 gene expression in polycystic ovary syndrome and endometrial cancer endometrium, and to correlate endometrial sterol regulatory element binding protein-1 gene expression with serum lipid profiles. 28176325 2017
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 GeneticVariation disease BEFREE Through sequence analysis, we found 10 SNPs of SREBF-1 associated with EC, including 3 new SNPs. 24614076 2014
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 Biomarker disease BEFREE In the present study, we detected expression of SIRT1 in endometrial cancer (EC) and illustrated the relationship between SIRT1 and SREBP1, which indicated that SIRT1 could stimulate endometrial tumor growth through the lipogenic pathway. 25270091 2014
CUI: C0476089
Disease: Endometrial Carcinoma
Endometrial Carcinoma
0.070 Biomarker disease BEFREE Taken together, our results show that SREBP1 is essential for EC cell growth both in vitro and in vivo, suggesting that SREBP1 activity may be a novel therapeutic target for endometrial cancers. 22672904 2012